These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24788661)

  • 1. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Sungkanuparph S
    J Antimicrob Chemother; 2014 Aug; 69(8):2195-201. PubMed ID: 24788661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
    Manosuthi W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2015 Jan; 46(1):19-26. PubMed ID: 26513901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
    Rodríguez-Nóvoa S; Labarga P; Soriano V; Egan D; Albalater M; Morello J; Cuenca L; González-Pardo G; Khoo S; Back D; Owen A
    Clin Infect Dis; 2009 Jun; 48(11):e108-16. PubMed ID: 19400747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.
    Nishijima T; Hayashida T; Kurosawa T; Tanaka N; Oka S; Gatanaga H
    PLoS One; 2015; 10(11):e0141931. PubMed ID: 26535588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
    Likanonsakul S; Suntisuklappon B; Nitiyanontakij R; Prasithsirikul W; Nakayama EE; Shioda T; Sangsajja C
    PLoS One; 2016; 11(1):e0147724. PubMed ID: 26807589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
    Lê MP; Landman R; Koulla-Shiro S; Charpentier C; Sow PS; Diallo MB; Ngom Gueye NF; Ngolle M; Le Moing V; Eymard-Duvernay S; Benalycherif A; Delaporte E; Girard PM; Peytavin G;
    J Antimicrob Chemother; 2015 May; 70(5):1517-21. PubMed ID: 25583749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
    Nishijima T; Komatsu H; Higasa K; Takano M; Tsuchiya K; Hayashida T; Oka S; Gatanaga H
    Clin Infect Dis; 2012 Dec; 55(11):1558-67. PubMed ID: 22955427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
    Pradat P; Le Pogam MA; Okon JB; Trolliet P; Miailhes P; Brochier C; Maynard M; Bailly F; Zoulim F; Cotte L
    J Viral Hepat; 2013 Sep; 20(9):650-7. PubMed ID: 23910650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort.
    da Rocha IM; Gasparotto AS; Lazzaretti RK; Notti RK; Sprinz E; Mattevi VS
    Pharmacogenet Genomics; 2015 Nov; 25(11):541-7. PubMed ID: 26287941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
    Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
    JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
    Girard PM; Cabié A; Michelet C; Verdon R; Katlama C; Mercié P; Morand-Joubert L; Pétour P; Monchecourt F; Chêne G; Trylesinski A;
    J Antimicrob Chemother; 2009 Jul; 64(1):126-34. PubMed ID: 19403652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.
    Bartlett JA; Chen SS; Quinn JB
    HIV Clin Trials; 2007; 8(4):221-6. PubMed ID: 17720662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
    Kinai E; Hanabusa H
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.